Adaptimmune Therapeutics (ADAP) Competitor Comparison
We are evaluating the key criteria listed to compare Adaptimmune Therapeutics (ADAP) against its competitors in the Biotechnology industry.
Market Capitalization
185 / 377Gross Profits
245 / 285Total Revenue
107 / 309EBITDA
214 / 345Free Cashflow
205 / 361Quick Ratio
273 / 366Earnings per Share
73 / 367Dividend yield
0 / 5Total Cash
182 / 367Performance 3 years
263 / 377Performance 5 years
242 / 377Performance 10 years
303 / 377Linearity 3 years
216 / 377Linearity 5 years
144 / 377Linearity 10 years
260 / 377Total Rank
180 / 377Dividend Rank
340 / 377Valuation Rank
356 / 377Piotroski Rank
70 / 377Muliplier Rank
254 / 377Valuation Rank - ADAP ranking 356 / 377
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.